Health law researcher Tim Caulfield tells Global News that, beyond GLP-1s, popular peptides lack good evidence. Health Canada has also warned about contaminated unauthorized products.
Recap by typeshit. Full story at Global News.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
A surgeon on social media says the FDA has received two death reports involving black-market retatrutide. No official FDA statement is linked.
A post on the trial pitting Lilly's tirzepatide against dulaglutide for cardiovascular outcomes in people with type 2 diabetes.
Medscape walks through the basics of orforglipron, Lilly's oral GLP-1 sold as Foundayo, as the pill moves toward approval in Europe.
Loading…